Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced it has completed enrollment in its first pivotal Phase 3 clinical trial, COVE-2, evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE